Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

10,950 total articles

Oracle Heading Toward a 2027 Inflection - A Patient Long Trade

Oracle Heading Toward a 2027 Inflection - A Patient Long Trade

Oracle (ORCL) looks materially cheaper than the market on headline multiples, but underlying cloud economics and the expected GenAI workload lift argue the stock needs more operational evidence before a full recovery. This trade idea recommends a patient, directional long with a disciplined stop and a target set for the 2027 inflection window.

ASML Is Pricier Than It Looks, But Fair for a Monopoly on EUV

ASML Is Pricier Than It Looks, But Fair for a Monopoly on EUV

ASML sits virtually alone in extreme ultraviolet (EUV) lithography and commands pricing power that justifies a premium multiple. At $1,749, the stock is not dirt cheap, but it is reasonably priced for a company with near-monopoly technology, strong cash generation and a central role in the AI-driven capex cycle. This trade idea lays out a disciplin…

HPE: Buy the Networking-Led AI Re-Rating — Tactical Swing Long

HPE: Buy the Networking-Led AI Re-Rating — Tactical Swing Long

HPE has quietly become a top pick for networking-driven, on-premises AI infrastructure. Backlog strength, an expanded product stack after the Juniper integration, and healthy cash flow create a setup for a swing trade. Valuation is no bargain, but the market is pricing in rapid growth; a disciplined entry, stop and target give asymmetric upside whi…

Agios: Mitapivat’s Indication Stack Is Turning Into a Commercial Flywheel — A Long Trade with Defined Risk

Agios: Mitapivat’s Indication Stack Is Turning Into a Commercial Flywheel — A Long Trade with Defined Risk

Mitapivat's expanding label set — recent FDA priority review for sickle cell plus durable hemoglobin and transfusion benefits — gives Agios ($AGIO) a chance to convert clinical momentum into accelerating sales. The balance sheet and recent revenue cadence reduce binary regulatory exposure, but valuation and competition keep risk elevated. Trade pla…

AMD Upgrade: AI Infrastructure Momentum Is Moving From Promise to Profits

AMD Upgrade: AI Infrastructure Momentum Is Moving From Promise to Profits

AMD is showing the early signs of an AI infrastructure flywheel: accelerating data-center traction, management tightening guidance upward, and improving cash generation. Valuation is rich but manageable given sustained earnings leverage. I upgrade to a tactical long with an explicit entry, stop and target and a 180-trading-day time frame to let the…

HCI Group: Deep-Value Insurance Compounder with an IPO Catalyst

HCI Group: Deep-Value Insurance Compounder with an IPO Catalyst

HCI Group (HCI) trades at single-digit P/E, carries minimal debt, and is generating outsized free cash flow relative to its $2.27B market cap. With an Exzeo IPO filing and a steady quarterly dividend, HCI looks positioned for a re-rating versus lagging insurance peers. This trade plan lays out a mid-term long with concrete entry, stop, and target l…

Cal-Maine: Buying the Recovery After a Brutal Egg Cycle

Cal-Maine: Buying the Recovery After a Brutal Egg Cycle

Cal-Maine (CALM) is the largest U.S. shell-egg producer and has been through an extreme earnings cycle as egg prices normalized from last year’s spike. The company still generates healthy cash flow, carries essentially no financial leverage, and trades at single-digit EV/EBITDA and low-teens P/E multiples. For disciplined traders, that combination …

Buy DEC: Capital-Light M&A and a High-Yield Re-rating Opportunity

Buy DEC: Capital-Light M&A and a High-Yield Re-rating Opportunity

Diversified Energy (DEC) is executing a shift toward capital-light growth by using asset-backed securitization and strategic partnerships to add production and reserves without issuing equity. At $15.05 and a market cap of $1.06B, the stock trades at a P/E of 2.3 and a 10% yield. We like a long trade into the company’s Q2 cadence and the expected c…

GlobalFoundries: Buy the Cycle, Not the AI Narrative

GlobalFoundries: Buy the Cycle, Not the AI Narrative

GlobalFoundries (GFS) looks like a cyclical value play after a sharp pullback from its May highs. The maker of differentiated foundry nodes is showing better margins driven by automotive and communications work, trades at a reasonable market cap of roughly $26.7B, and has technicals that favor a mean-reversion move. This trade is for investors who …

Nano Labs' AI Play Has Momentum: MoU, Product Launches and Insider Buying Create a High-Upside Swing Trade

Nano Labs' AI Play Has Momentum: MoU, Product Launches and Insider Buying Create a High-Upside Swing Trade

Nano Labs (NA) has stacked a string of tangible developments—an MoU to explore North American AI data centers, a new AI hardware product launch, a compliance-focused blockchain program and a sizeable insider buy. With a $44.6M market cap, a sub-$2 share price and heavy short interest, this is a high-risk, high-reward swing trade for disciplined tra…

10x Genomics Upgraded - Turnaround Confirmed, Now Buy Atera Execution

10x Genomics Upgraded - Turnaround Confirmed, Now Buy Atera Execution

10x Genomics has moved from recovery to expansion: a successful product cycle around Atera plus improving margins and positive free cash flow make a tactical long worthwhile. I upgrade the stock to a buy for a long-term trade tied to Atera commercialization milestones, with an explicit entry, stop and target to manage execution risk.

NICE: Profitable AI Growth Underpriced — A 180-Day Trade Plan

NICE: Profitable AI Growth Underpriced — A 180-Day Trade Plan

NICE Ltd. combines profitable enterprise software with accelerating AI product adoption and a manageable valuation. Recent weakness from a near-term earnings miss has blown off some optimism; that creates a tradeable opportunity. We outline a long trade with entry at $101, stop at $92 and a $130 target, and explain the catalysts and risks that make…

Lincoln National: Earnings Momentum, Cheap Multiples - A Tactical Long

Lincoln National: Earnings Momentum, Cheap Multiples - A Tactical Long

Lincoln National (LNC) reported recurring strength in annuities and group protection that has pushed statutory earnings higher, yet the stock trades at a single-digit P/E and below-book valuation. We view LNC as a tactical long for income and value-oriented traders, with a trade plan that captures upside as the market re-rates the insurer while lim…